Local Triamcinolone Injection in Active Thyroid Orbitopathy

Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01280214

Enrollment

Registered

2011-01-20

Start date

2011-02-28

Completion date

2013-02-28

Last updated

2011-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Disease

Brief summary

Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.

Detailed description

Local Steroid treatment may help in active thyroid orbitopathy. till today, systemic Steroids are the treatment for active thyroid orbitopathy which is associated with systemic adverse effects. In this study the investigators want to compare the effectiveness of local Triamcinolone therapy for active thyroid orbitopathy.

Interventions

DRUGTriamcinolone

Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age\>18 years. * Active thyroid orbitopathy according to clinical activity score\>=3.

Exclusion criteria

* Intraorbital or active infections. * Tuberculosis. * Other orbital disease. * Pregnancy. * Compressive optic neuropathy. * Systemic steroid therapy within 6 months of study start.

Design outcomes

Primary

Measure	Time frame	Description
Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy .	6 months	Every month, each participant will undergo several tests : blood sugar, full ocular examination, color test, visual field and ultrasound test for measuring the thickness of extraocular muscles.Clinical activity score for thyroid orbitopathy will be assesed too. The results of the clinical and ultrasonogrophic findings will determine the effectiveness of the treatment. A patient with deterioration of thyroid orbitopathy during the research, will be treated by systemic Steroids in addition to the local injections.

Secondary

Measure	Time frame	Description
To check if the level of TSH Receptor antibodies are affected by the local injection.	4 months	A blood test for TSH Receptor antibodies will be taken for every patient at the beginnig of the research and after 4 months.

Contacts

Primary ContactDaniel Briscoe, MD

daniel_br@clalit.org.il972-4-6494344

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026